Tagging the Donkey
San Diego, California
It’s time for the infamous ASH Dash with the abstract drop today!
We’ll be posting our series of in-depth previews around various themes/tumour targets and annual trend analysis in due course.
For now we wanted to highlight an emerging approach, which may well turn out to be disruptive in certain hematologic malignancies.
The catch? It could happen sooner than you think.
What’s more, there’s data at ASH – making this our first ASH Preview, albeit of a slightly different kind from prior years…
In our latest expert interview we learn how, why, and when this technology could change the way we treat patients and pave the way forward for a new wave of biotechs developing these products.
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
